Fatty liver disease, affecting roughly 25% of the global population as of 2021, starts often as NAFLD - a condition marked by lipid accumulation but minimal inflammation. It can escalate to NASH, which involves liver inflammation and cellular damage. The progression is driven by factors like toxic lipid accumulation (lipotoxicity), increased inflammation, and insulin resistance                 . Effective lipid management is vital to prevent this progression and serious outcomes such as fibrosis, cirrhosis, and liver cancer.